MedTrace Logo

Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency

NCT00446485 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2015-09-28

No results posted yet for this study

Summary

The purpose of the study is to determine weather Ginkgo biloba standardized extract (24% ginkoflavonoglicozides and 6% terpenes) is effective in treatment of cognitive and concentration impairment

Conditions

Interventions

DRUG

Ginkgo biloba standardized extract 24/6

tablets, 120 mg/day (60 mg two times daily) during 6 months

DRUG

Ginkgo Biloba standardized extract 24/6

tablets, 60 mg/day during 6 months

DRUG

placebo

placebo during 6 months

Sponsors & Collaborators

  • Milsing d.o.o.

    lead OTHER

Principal Investigators

  • Vida Demarin, MD PHD · University Department of Neurology, Sestre milosrdnice University Hospital, Vinogradska 29, HR-10000 Zagreb, Croatia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00446485 on ClinicalTrials.gov